Jonathan Edward Campbell

Jonathan Edward Campbell

Associate Professor in Medicine

Appointments and Affiliations

  • Associate Professor in Medicine
  • Associate Research Professor in Pharmacology & Cancer Biology
  • Member of Duke Molecular Physiology Institute

Contact Information

  • Email Address: jonathan.campbell@duke.edu

Education

  • Ph.D. York University in Toronto (Canada), 2010

Representative Publications

  • Campbell, JE; Müller, TD; Finan, B; DiMarchi, RD; Tschöp, MH; D'Alessio, DA, GIPR/GLP-1R dual agonist therapies for diabetes and weight loss-chemistry, physiology, and clinical applications., Cell Metab, vol 35 no. 9 (2023), pp. 1519-1529 [10.1016/j.cmet.2023.07.010] [abs].
  • Le, TDV; Fathi, P; Watters, AB; Ellis, BJ; Besing, G-LK; Bozadjieva-Kramer, N; Perez, MB; Sullivan, AI; Rose, JP; Baggio, LL; Koehler, J; Brown, JL; Bales, MB; Nwaba, KG; Campbell, JE; Drucker, DJ; Potthoff, MJ; Seeley, RJ; Ayala, JE, Fibroblast growth factor-21 is required for weight loss induced by the glucagon-like peptide-1 receptor agonist liraglutide in male mice fed high carbohydrate diets., Molecular Metabolism, vol 72 (2023) [10.1016/j.molmet.2023.101718] [abs].
  • El, K; Douros, JD; Willard, FS; Novikoff, A; Sargsyan, A; Perez-Tilve, D; Wainscott, DB; Yang, B; Chen, A; Wothe, D; Coupland, C; Tschöp, MH; Finan, B; D'Alessio, DA; Sloop, KW; Müller, TD; Campbell, JE, The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets., Nature Metabolism, vol 5 no. 6 (2023), pp. 945-954 [10.1038/s42255-023-00811-0] [abs].
  • Capozzi, ME; D'Alessio, DA; Campbell, JE, The past, present, and future physiology and pharmacology of glucagon., Cell Metab, vol 34 no. 11 (2022), pp. 1654-1674 [10.1016/j.cmet.2022.10.001] [abs].
  • Campbell, JE, Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms., Molecular Metabolism, vol 46 (2021) [10.1016/j.molmet.2020.101139] [abs].